Project Grant F32AI194768
- This $492,000 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to conduct biochemical and structural characterization of the elongasome and divisome protein complexes in Mycobacterium tuberculosis (MTB) and the model organism Mycobacterium smegmatis. The research will use bacterial genetics and endogenous protein purifications to understand how these critical protein systems coordinate and interact to...
- This $227,096 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by the University of California, Berkeley to investigate nutrient acquisition strategies utilized by the tuberculosis pathogen Mycobacterium tuberculosis (MTB) during infection of human macrophages. The researchers have developed a novel genetic screening technique called Random Barcode Transposon Site Sequencing (RB-TnSeq) to...
- This Project Grant award of $562,123.00, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports research to define the roles of small KH-domain RNA binding proteins in mycobacteria. The research, conducted by Worcester Polytechnic Institute, aims to determine the functional properties, target RNA binding, and impacts on RNA stability and cellular function of two mycobacterial RNA binding proteins,...
- This Project Grant award of $423,500 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to determine the potential of phenylalanine (Phe) biosynthesis as a novel drug target for treating tuberculosis caused by Mycobacterium tuberculosis (MTB). The award will enable the development of MTB strains that conditionally express enzymes in the Phe biosynthesis pathway, which will be used to...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID, CFDA 93.855 Allergy and Infectious Diseases Research), provides $466,500.00 in funding to the University of North Carolina at Chapel Hill (UNC-CH) to conduct research on the bacterial genetic basis underlying the transmissibility of tuberculosis (TB). The project aims to: (1) identify key mutations that drive high transmissibility in Mycobacterium tuberculosis (MTB) using a global collection of...
- This Project Grant award of $104,262, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to explore the relationship between genetic variants, transcriptional responses, and tuberculosis (TB) infection outcomes in macrophages derived from genetically diverse mice. The project aims to understand the basis for variability in TB infection outcomes, which may help identify ways to...
- This federal Project Grant award of $819,998.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), to The Regents of the University of California, San Francisco. The purpose of the award is to conduct research to understand how Mycobacterium tuberculosis (M. tuberculosis) infection triggers host cell death mechanisms, with the goal of identifying new therapeutic targets to augment protective...
- This $811,396 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases under CFDA 93.855 Allergy and Infectious Diseases Research, is focused on understanding the mechanisms of lipid/metabolite and drug transport in Mycobacterium tuberculosis and related mycobacteria. The major objectives are to establish the molecular mechanisms and structures of three specific MMPL transporter proteins and their complexes with interacting partner proteins. Key activities include...
- The federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is providing $209,757 to The Trustees of Columbia University in the City of New York, Health Sciences Division, from September 15, 2025 to August 31, 2030. The funding supports mentorship and training to develop a new cadre of researchers focused on addressing the challenges of multidrug-resistant tuberculosis (MDR-TB) within the global HIV...
- This $375,420 Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports research on the structural bases for protein synthesis quality control in bacteria. The project aims to elucidate the mechanisms by which translation factors, such as Release Factor 3 (RF3) and Initiation Factor 2 (IF2), monitor the accuracy and fidelity of protein synthesis by the bacterial ribosome. The award,...
EXPLORING LEADERLESS MRNA TRANSLATION, A POTENTIAL ACHILLES HEEL OF MYCOBACTERIA - PROJECT SUMMARY/ABSTRACT TUBERCULOSIS (TB) REMAINS A SIGNIFICANT GLOBAL HEALTH THREAT, CAUSING APPROXIMATELY 1.5 MILLION DEATHS ANNUALLY, WITH TREATMENT COMPLICATED BY THE RISE OF DRUG-RESISTANCE MYCOBACTERIUM TUBERCULOSIS (MTB) STRAINS. A COMMON TARGET FOR ANTIBIOTICS IS THE BACTERIAL RIBOSOME, AND MYCOBACTERIAL RIBOSOMES HAVE UNIQUE FEATURES AND FUNCTIONS, WHICH MAY BE EXPLOITED TO DEVELOPMENT MORE EFFECTIVE TREATMENTS. ONE SUCH EXAMPLE IS THE PREVALENCE OF SO- CALLED LEADERLESS MRNAS, (LMRNA) WHICH LACK THE 5' UNTRANSLATED REGION AND SHINE-DALGARNO SEQUENCE USED DURING CANONICAL PROTEIN TRANSLATION INITIATION. THIS PROJECT SEEKS TO DEVELOP AN UNDERSTANDING OF THE MECHANISM OF LMRNA TRANSLATION IN MYCOBACTERIA AND UNDERSTAND HOW THIS FORM OF TRANSLATION IS REGULATED. I HYPOTHESIZE THAT THERE ARE UNIQUE STRUCTURES IN THE MYCOBACTERIAL RIBOSOME THAT ALLOW FOR EFFICIENT TRANSLATION OF LMRNAS AND THAT LMRNAS ARE OF PARTICULAR RELEVANCE DURING STRESS OR INFECTION CONDITIONS. AIM 1 WILL USE REVERSE GENETICS TO SCREEN CANDIDATE REGULATORS OF LMRNA TRANSLATION IN MYCOBACTERIA USING A PAIR OF ORTHOGONAL REPORTERS FOR LEADERLESS TRANSLATION. REGULATORS VALIDATED BY BOTH REPORTERS WILL BE FURTHER INVESTIGATED BY RIBOSOME PROFILING. AIM 2 WILL USE FORWARD GENETICS IN THE FORM OF A CRISPRI SCREEN TO IDENTIFY UNKNOWN REGULATORS OF LMRNA TRANSLATION IN MYCOBACTERIA USING A LEADERLESS SACB REPORTER. HITS FROM THE SCREEN WILL BE VALIDATED USING AN ORTHOGONAL FLUORESCENT LEADERLESS TRANSLATION REPORTER, AND CONFIRMED HITS WILL BE FURTHER ANALYZED USING RIBOSOME PROFILING. AIM 3 WILL LEVERAGE CRYOEM TO IDENTIFY STRUCTURAL COMPONENTS OF THE MYCOBACTERIAL RIBOSOME THAT CONTRIBUTE TO EFFECTIVE LEADERLESS TRANSLATION, FIRST BY ISOLATING AND COMPARING STRUCTURES OF THE RIBOSOME ON CANONICAL AND LEADERLESS MRNA TRANSCRIPTS AND LATER BY SOLVING STRUCTURES OF RIBOSOMES LACKING PROMISING VALIDATED HITS FROM AIMS 1 AND 2. THIS WORK WILL ALLOW FOR THE IDENTIFICATION OF NOVEL THERAPEUTIC TARGETS ON THE MYCOBACTERIAL RIBOSOME, SUPPORTING THE BROAD NIH MISSION TO REDUCE THE BURDEN OF INFECTIOUS DISEASES. THIS PROJECT COMBINES MY RESEARCH INTERESTS IN INFECTIOUS DISEASE, PROTEIN TRANSLATION, AND BACTERIAL GENETICS WHILE INCREASING MY FAMILIARITY WITH STRUCTURAL BIOLOGY. THIS AWARD WILL SUPPORT MY LONG-TERM CAREER DEVELOPMENT INTO AN INDEPENDENT ACADEMIC RESEARCHER, AND I WILL SUPPLEMENT IT WITH CONTINUED MENTORING AND TEACHING, AS WELL AS TAKING ADVANTAGE OF THE CAREER AND PROFESSIONAL DEVELOPMENT PROGRAMS AVAILABLE AT UCSF.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $75.1k | 8/8/25 |